Humacyte (HUMA) traded up 5.33 % during a 24 hours period ending at 04:15 PM Central Europe on Monday 26th. One Humacyte stock can currently be bought for about USD 0.4 on popular exchanges. Current supply of Humacyte stocks is 278 mn. Humacyte has a current market capitalization of USD 121 mn and approximately USD 1.1 mn worth of Humacyte was traded on exchanges in the last 24 hours. Since last month end, Humacyte has traded -23.55 % down. Simple moving average of last 200 days is at USD 0.82. The highest price of past 52 weeks was recorded at USD 1.78 on 10/29/2025. 52 weeks low was at USD 0.34 on 10/14/2026.

Here is how related stocks have performed in the past 24 hours:

  • Journey Medical (DERM) traded down -1.38 % and now trades at USD 4.97. Journey Medical has a market capitalisation of USD 141.7 mn.

  • Eagle Nuclear Energy (NUCL) traded down -2.45 % and now trades at USD 4.68. Current market capitalisation for Eagle Nuclear Energy is USD 141.4 mn.

  • Maxcyte (MXCT) traded down -2.1 % and now trades at USD 1.44. Current market capitalisation for Maxcyte is USD 144.5 mn. MaxCyte Inc. is scheduled to release its financial statements for the quarter ending September 30 2026 on November 10, 2026. Analysts anticipate a modest improvement in earnings, projecting a per‑share loss that is slightly less severe than the previous year’s loss. Revenue forecasts indicate a moderate increase from the prior quarter, with analysts expecting a rise in sales, although the forecasted figure is slightly below the previous year’s total. For the current fiscal year, consensus estimates suggest a continued loss on a per‑share basis, but at a less negative level compared with the same period last year. Revenue guidance for the year is slightly below last year’s reported amount, reflecting a cautious outlook as the company prepares to disclose its upcoming financial results.

  • Acumen (ABOS) traded down -3.88 % and now trades at USD 2.02. Acumen has a market capitalisation of USD 143.2 mn.

  • Macrogenics (MGNX) traded down -38.02 % and now trades at USD 2.01. Current market capitalisation for Macrogenics is USD 143.3 mn.

About Humacyte

Humacyte, Inc. is a biotech company that specializes in developing and manufacturing implantable bioengineered human tissues. The company serves customers globally and can be accessed through its website at www.humacyte.com . Humacyte is listed on the Nasdaq stock exchange.